S-1 + bevacizumab + carboplatin

This is a combination therapy consisting of three components:\n\n1. **S-1** - An oral anticancer drug that combines tegafur (a prodrug of fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase), and potassium oteracil (an inhibitor of the phosphorylation of fluorouracil in the gastrointestinal tract) in a molar ratio of 1:0.4:1. S-1 is a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine that provides sustained 5-FU concentrations in blood.\n\n2. **Bevacizumab** - A monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis.\n\n3. **Carboplatin** - A platinum-based chemotherapy agent that forms intrastrand DNA crosslinks, inhibiting DNA replication and transcription.

Other names

tegafur/gimeracil/oteracil + bevacizumab + carboplatin